HSP90AB1 and cancer: As HSP90 has been considered as an anti-cancer target for more than 20 years15, a series of HSP90 inhibitors have been discovered, including the first generation inhibitor Geldanamycin and its derivatives (17-DMAG, 17-AAG, etc.), and the second generation inhibitors STA-9090, NVP-AUY92226.